Inotiv Inc (NOTV)
1.93
-0.21
(-9.81%)
USD |
NASDAQ |
May 17, 16:00
1.935
0.00 (0.00%)
After-Hours: 20:00
Inotiv SG&A Expense (Quarterly): 25.28M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 25.28M |
September 30, 2023 | 28.69M |
June 30, 2023 | 31.36M |
March 31, 2023 | 33.79M |
December 31, 2022 | 32.80M |
September 30, 2022 | 30.65M |
June 30, 2022 | 26.45M |
March 31, 2022 | 25.99M |
December 31, 2021 | 15.99M |
September 30, 2021 | 6.751M |
June 30, 2021 | 8.144M |
March 31, 2021 | 6.49M |
December 31, 2020 | 5.507M |
September 30, 2020 | 5.473M |
June 30, 2020 | 5.316M |
March 31, 2020 | 5.226M |
December 31, 2019 | 4.335M |
September 30, 2019 | 5.191M |
June 30, 2019 | 3.251M |
March 31, 2019 | 2.865M |
December 31, 2018 | 2.254M |
September 30, 2018 | 3.079M |
June 30, 2018 | 1.515M |
March 31, 2018 | 1.481M |
December 31, 2017 | 1.431M |
Date | Value |
---|---|
September 30, 2017 | 1.447M |
June 30, 2017 | 1.467M |
March 31, 2017 | 1.378M |
December 31, 2016 | 1.661M |
September 30, 2016 | 1.761M |
June 30, 2016 | 1.435M |
March 31, 2016 | 1.446M |
December 31, 2015 | 1.356M |
September 30, 2015 | 1.861M |
June 30, 2015 | 1.416M |
March 31, 2015 | 1.636M |
December 31, 2014 | 1.571M |
September 30, 2014 | 1.758M |
June 30, 2014 | 1.561M |
March 31, 2014 | 1.737M |
December 31, 2013 | 1.54M |
September 30, 2013 | 1.689M |
June 30, 2013 | 1.47M |
March 31, 2013 | 1.144M |
December 31, 2012 | 1.468M |
September 30, 2012 | 1.696M |
June 30, 2012 | 1.863M |
March 31, 2012 | 2.622M |
December 31, 2011 | 2.606M |
September 30, 2011 | 2.446M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
3.251M
Minimum
Jun 2019
33.79M
Maximum
Mar 2023
16.14M
Average
8.144M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
Biolase Inc | 6.579M |
Akoya Biosciences Inc | 19.86M |
Durect Corp | 3.136M |
Macrogenics Inc | 14.71M |
Candel Therapeutics Inc | 3.80M |